Literature DB >> 31687337

Mitochondrial myopathy plus due to the variant m.586G > A in MT-TF.

Giulia Barcia1, Zahra Assouline1, Alessandra Pennisi1, Julie Steffann1, Nathalie Boddaert1, Cyril Gitiaux1, Agnès Rötig1, Jean-Paul Bonnefont1, Arnold Munnich1.   

Abstract

Entities:  

Year:  2019        PMID: 31687337      PMCID: PMC6819737          DOI: 10.1016/j.ymgmr.2019.100522

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


× No keyword cloud information.
To the Editor: Sir, We have read with interest the Letter of Dr. J. Finsterer [1] regarding the report of Barcia et al. on a novel case of de novo MTTF mutation [2]. Our report was aimed at emphasizing the striking clinical differences between two individuals carrying the same mitochondrial MTTF mutation (m.586G > A), namely a childhood-onset form of mitochondrial myopathy [2] and a late-onset form of progressive neurodegenerative disorder with akinesia-rigidity, abnormal movements, dementia and psychiatric disorder in a 57 yrs-old woman [3]. Whether intrinsic mitochondrial genetic factors (such as heteroplasmy and mitotic segregation) or hitherto unknown nuclear factors accounted for those strikingly different presentations remains unanswered. Similarly, whether brisk deep tendon reflexes of our patient should be considered as “quadri-spasticity” and episodes of migraine-like headaches and vomiting episodes, be regarded as the hallmark of “CNS involvement” is also debatable, especially as our patient had consistently elevated plasma lactate, normal brain MRI and normal schooling. Whatever the opinions, this issue offers the opportunity to recall that mitochondrial respiratory chain deficiency can give rise to virtually any symptom, in any organ or tissue, at any age, from the neonatal and even antenatal period [4] to late childhood and adulthood. In early-onset pediatric forms of the disease, the clinical expression of the primarily affected organ is at the forefront of the scene, possibly hiding CNS involvement (bone marrow in Pearson syndrome, liver in hepatic failure, heart in mitochondrial cardiomyopathy). In our pediatric cohort, CNS involvement frequently appears later in the course of the disease, especially in chronic forms or after transplantation of the life-threatening organ [5]. Also, as far as clinical management of the children is concerned, putting forward CNS involvement at early stages of the disease inevitably leads to a form of discouragement that we do our best to postpone.
  5 in total

1.  Mitochondrial transfer RNA(Phe) mutation associated with a progressive neurodegenerative disorder characterized by psychiatric disturbance, dementia, and akinesia-rigidity.

Authors:  Tim M Young; Emma L Blakely; Helen Swalwell; Janet E Carter; Luke D Kartsounis; Dominic G O'Donovan; Douglass M Turnbull; Robert W Taylor; Rajith N de Silva
Journal:  Arch Neurol       Date:  2010-11

2.  Increased incidence of obstetric complications in women carrying mitochondrial DNA mutations: a retrospective cohort study in a single tertiary centre.

Authors:  M Kuleva; S Ben Miled; J Steffann; J P Bonnefont; S Rondeau; Y Ville; A Munnich; L J Salomon
Journal:  BJOG       Date:  2019-02-07       Impact factor: 6.531

3.  Mitochondrial myopathy plus due to the variant m.586G > A in MT-TF.

Authors:  Josef Finsterer
Journal:  Mol Genet Metab Rep       Date:  2019-09-11

4.  Expanding the clinical spectrum of MTTF mutations.

Authors:  Giulia Barcia; Zahra Assouline; Alessandra Pennisi; Julie Steffann; Nathalie Boddaert; Cyril Gitiaux; Agnès Rötig; Jean-Paul Bonnefont; Arnold Munnich
Journal:  Mol Genet Metab Rep       Date:  2019-08-13

5.  Next-generation sequencing reveals DGUOK mutations in adult patients with mitochondrial DNA multiple deletions.

Authors:  Dario Ronchi; Caterina Garone; Andreina Bordoni; Purificacion Gutierrez Rios; Sarah E Calvo; Michela Ripolone; Michela Ranieri; Mafalda Rizzuti; Luisa Villa; Francesca Magri; Stefania Corti; Nereo Bresolin; Vamsi K Mootha; Maurizio Moggio; Salvatore DiMauro; Giacomo P Comi; Monica Sciacco
Journal:  Brain       Date:  2012-10-04       Impact factor: 13.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.